All In Biotech

Drug Trial Radar · NCT06370715

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India

A 26- Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

153

Actual

Start

Apr 18, 2024

Primary completion

Sep 2, 2025

Study completion Sep 2, 2025

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Cipla Ltd.
First posted
Apr 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin Lispro-aabcDrug

    Administered subcutaneously

  • Insulin GlargineDrug

    Administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)Time frame: Baseline through Week 26
  2. Rate of Documented Hypoglycemia With Blood Glucose <54 mg/dLTime frame: Baseline through Week 26

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Osmania Medical College & Hospital

    Hyderabad, Andhra Pradesh, India

  • King George Hospital, Visakhapatnam

    Visakhapatnam, Andhra Pradesh, India

  • Diabetes Research Centre

    Royapuram, Chennai India, India

  • Vijyaratna Dibetes Diagnosis Treatment Centre

    Ahmedabad, Gujrat, India

  • Center for Diabetes and Endocrine Care

    Bengaluru, Karnataka, India

  • Sahyadri Super Speciality Hospital

    Pune, Maharashtra, India

  • Chellaram Diabetes Institute

    Pune, Maharashtra, India

  • S. P. Medical College & A G Hospital

    Bikaner, Rajasthan, India

  • Rajasthan University of Health Sciences

    Jaipur, Rajasthan, India

  • Kovai Diabetes Speciality Center and Hospital

    Coimbatore, Tamil Nadu, India

  • Brij Medical Center Pvt. Ltd.

    Kanpur, Uttar Pradesh, India

  • Medical College & Hospital, Kolkata

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.